

COVID-19

The clinical need in hospitalised patients

There is an urgent need for new therapies to treat hospitalised COVID-19 patients to prevent disease progression, accelerate hospital discharge and enable patients to quickly return to usual activities.

Despite vaccination programmes and the availability of new early interventions, thousands of patients are being hospitalised with COVID-19 every day.^{1,2} These hospitalisations continue to impose severe care burdens on families and hospitals and cost burdens on patients and payers.

- Hospitalised patients with COVID-19 are requiring a significant proportion of hospital capacity, impacting routine hospital care.³
- In addition to the human cost, the financial burden of caring for patients hospitalised with COVID-19, particularly those in ICUs, is significant:
 - Even for noncomplex COVID-19 hospitalisations, the average billing costs exceed six figures in several US states, ranging from \$31,339 to \$111,213 around the country.⁵
 - Complex cases are much more expensive, with average costs ranging by state from \$131,965 to \$472,213.⁵

- Recent market research by IQVIA indicates that current COVID-19 therapies do not fully meet the needs of patients or doctors in hospitals.¹⁰
- Some of the limitations of these current therapies include:
 - Lack of efficacy against new variants;⁶
 - Need for safety monitoring;⁶
 - Need to administer in the hospital setting;⁶
 - Potential for the development of viral resistance;⁷
 - Limited target patient populations⁸; and
 - Tolerability concerns.⁹
- New therapies that effectively treat hospitalised COVID-19 patients could help address this urgent clinical need by:
 - Preventing the progression to severe disease;
 - Reducing the length of hospital stays; and
 - Reducing the care and financial burdens associated with hospitalisation.

“The need for treatments for all stages of the disease is, in fact, more pronounced than ever. Never in the history of infectious-disease control have we been satisfied with just one set of tools.”

Rachel Cohen
 Director of Drugs for
 Neglected Diseases Initiative



For more information, please visit www.synairgen.com

1. Centers for Disease Control and Prevention. COVID Data Tracker Weekly Review. November 2021. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html> (Accessed: 9 November 2021).
 2. UK Government. Healthcare in United Kingdom. November 2021. <https://coronavirus.data.gov.uk/details/healthcare> (Accessed: 9 November 2021).
 3. World Health Organization. Second round of the national pulse survey on continuity of essential health services during the COVID-19 pandemic. Interim Report. January–March 2021. (WHO/2019-nCoV/

EHScontinuity/survey/2021.1). <https://www.who.int/publications/item/WHO-2019-nCoV-EHS-continuity-survey-2021.1> (Accessed: 9 November 2021).
 4. Tsai Y, Vogt TM, Zhou F. Patient Characteristics and Costs Associated With COVID-19-Related Medical Care Among Medicare Fee-for-Service Beneficiaries. *Ann Intern Med.* 2021;174:1101–1109.
 5. Ohsfeldt RL, Choong CK, Mc Collam PL, et al. Inpatient Hospital Costs for COVID-19 Patients in the United States. *Adv Ther.* 2021;38:5557–5595.
 6. Sanders JM, Monogue ML, Jodlowski TZ and Cutrell JB. Pharmacologic

Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA.* 2020;323:1824–1836.
 7. Knight GM, Glover RE, McQuaid CF, et al. Antimicrobial resistance and COVID-19: Intersections and implications. *Elife.* 2021;10:e64139.
 8. Summary of COVID-19 medicines guidance: Critical care. Available at: <https://www.sps.nhs.uk/articles/summary-of-covid-19-medicines-guidance-critical-care/> (Accessed: 9 November 2021).
 9. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature.* 2021;593:130–135.
 10. IQVIA market research Q4 2021. Data on File.